Del. Jury Finds Flexus Took Incyte Secrets, Nixes Damages
A Delaware jury agreed Wednesday that Flexus Biosciences Inc. and two top officers misappropriated cancer drug trade secrets from Incyte Corp., but rejected unjust enrichment claims that could have rung up...To view the full article, register now.
Already a subscriber? Click here to view full article